{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05382910",
      "orgStudyIdInfo": {
        "id": "MG-K10-AS-2"
      },
      "organization": {
        "fullName": "Shanghai Mabgeek Biotech.Co.Ltd",
        "class": "OTHER_GOV"
      },
      "briefTitle": "A Study of MG-K10 in Subjects With Asthma",
      "officialTitle": "Phase Ib/II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Asthmatic Subjects"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-08",
      "overallStatus": "UNKNOWN",
      "lastKnownStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2022-07-05",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-12-20",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2024-06-20",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2022-05-11",
      "studyFirstSubmitQcDate": "2022-05-16",
      "studyFirstPostDateStruct": {
        "date": "2022-05-19",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-08-17",
      "lastUpdatePostDateStruct": {
        "date": "2023-08-21",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Shanghai Mabgeek Biotech.Co.Ltd",
        "class": "OTHER_GOV"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "This study is a phase Ib/II clinical trial conducted in Chinese adult asthmatic subjects to evaluate the preliminary efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of asthma.",
      "detailedDescription": "The study was conducted in two phases: the Phase Ib study focused on the safety and tolerability of MG-K10 in adult asthma subjects. Phase II study focused on the preliminary efficacy in adults with moderate to severe asthma."
    },
    "conditionsModule": {
      "conditions": [
        "Asthma"
      ],
      "keywords": [
        "asthma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "About 180 subjects with moderate-to-severe asthma who meet the inclusion criteria will be selected for this study, according to 1:1:1 Randomly assigned to one of the MG-K10 Q2W group, the MG-K10 Q4W group, and the placebo group, with approximately 60 subjects in each group. The Q2W group will receive MG-K10 300mg subcutaneous injection every 2 weeks; Q4W group will receive MG-K10 300mg subcutaneous injection (every 4 weeks) + 2ml placebo subcutaneous injection ; the placebo group will receive 2 ml of placebo subcutaneously administered every 2 weeks. All three groups were followed up for 8 weeks after 24 weeks of treatment.",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 180,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "MG-K10 Q2W",
          "type": "EXPERIMENTAL",
          "description": "Received MG-K10 300 mg subcutaneous injection every 2 weeks",
          "interventionNames": [
            "Drug: MG-K10"
          ]
        },
        {
          "label": "MG-K10 Q4W",
          "type": "EXPERIMENTAL",
          "description": "Received MG-K10 300 mg subcutaneous injection every 4 weeks",
          "interventionNames": [
            "Drug: MG-K10",
            "Drug: Placebo"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "The placebo group will receive 2 ml of placebo subcutaneously administered every 2 weeks.",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "MG-K10",
          "description": "MG-K10 Humanized Monoclonal Antibody Injection",
          "armGroupLabels": [
            "MG-K10 Q2W",
            "MG-K10 Q4W"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Placebo",
          "armGroupLabels": [
            "MG-K10 Q4W",
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Absolute Change from baseline in pre-bronchodilator FEV1",
          "description": "Absolute change from baseline in pre-bronchodilator FEV1 in each study group at 12 week of MG-K10 treatment compared with placebo",
          "timeFrame": "12 week"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Absolute Change from baseline in pre-bronchodilator FEV1",
          "description": "Absolute change from baseline in pre-bronchodilator FEV1 in each study group at 4,8,16,20,24,28,32 week of MG-K10 treatment compared with placebo",
          "timeFrame": "4,8,16,20,24,28,32 week"
        },
        {
          "measure": "Percent change from baseline in pre-bronchodilator FEV1",
          "description": "at 4,8,16,20,24,28,32 week of MG-K10 treatment compared with placebo，Percent change from baseline in pre-bronchodilator FEV1",
          "timeFrame": "4,8,16,20,24,28,32 week"
        },
        {
          "measure": "peak morning and evening expiratory flow (PEF)",
          "description": "Change from peak morning and evening expiratory flow (PEF) compared with baseline (absolute and percentage)",
          "timeFrame": "4,8,12,16,20,24,28,32 week"
        },
        {
          "measure": "the Annualized rate of severe asthma acute event",
          "description": "The annualized rate of severe asthma acute event within 24 weeks and 25 to 32 weeks of treatment",
          "timeFrame": "24 weeks and 25 to 32 weeks"
        },
        {
          "measure": "Annualized rate of the event of loss of asthma control (LOAC)",
          "description": "the annualized rate of the event of loss of asthma control (LOAC) at 24 weeks and 25 to 32 weeks of treatment",
          "timeFrame": "24 weeks and 25 to 32 weeks"
        },
        {
          "measure": "Time of the first severe asthma acute event",
          "description": "Time of the first severe asthma acute event",
          "timeFrame": "32 weeks"
        },
        {
          "measure": "Time of first loss of asthma control (LOAC)",
          "description": "Time of first loss of asthma control (LOAC)",
          "timeFrame": "32weeks"
        },
        {
          "measure": "asthma Control Questionnaire 5 (ACQ-5 score 0-30) changes in score",
          "description": "There are 5 questions in ACQ5, It is a questionnaire used to evaluate the degree of asthma control. Each question is scored from 0 to 6 (on a 7-point scale) according to its severity. The higher the score, the less satisfactory symptom control",
          "timeFrame": "4, 8, 12, 16, 20, 24, 28, and 32 weeks"
        },
        {
          "measure": "Morning/evening asthma symptom score",
          "description": "Patients will record total symptom scores in morning（a 0-4 scale, with 0=no symptoms, 4=inability to fall asleep at night due to symptoms) and evening (a 0-4 scale, with 0=no symptoms, 4=severe symptoms, unable to work or perform daily activities)",
          "timeFrame": "24 and 32 week"
        },
        {
          "measure": "Daily use of first aid medicine spray",
          "description": "Daily use of first aid medicine spray compared with baseline",
          "timeFrame": "24 and 32 week"
        },
        {
          "measure": "Incidence of Adverse events (AEs)",
          "description": "Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing",
          "timeFrame": "32 weeks"
        },
        {
          "measure": "Pharmacokinetic concentration",
          "description": "To evaluate the Pharmacokinetic concentration of MG-K10 for each dose group. Population pharmacokinetic analysis is performed using a nonlinear mixed-effects model",
          "timeFrame": "32 weeks"
        },
        {
          "measure": "Fractional exhaled nitric oxide (FeNO)",
          "description": "At each evaluation time point, the changes of Fractional exhaled nitric oxide(FeNO) were compared with baseline in each group",
          "timeFrame": "32 weeks"
        },
        {
          "measure": "thymus activation regulated chemokine (TARC)",
          "description": "At each evaluation time point, the changes of thymus activation regulated chemokine (TARC) were compared with baseline in each group",
          "timeFrame": "32 weeks"
        },
        {
          "measure": "serum immunoglobulin E (IgE)",
          "description": "At each evaluation time point, the changes of serum immunoglobulin E (IgE)were compared with baseline in each group",
          "timeFrame": "32 weeks"
        },
        {
          "measure": "Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs)",
          "description": "Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs) (if applicable)",
          "timeFrame": "32 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Asthma diagnosed according to the 2021 version of the GINA guidelines for at least 1 year;\n* 1 second forced expiratory volume (FEV1) before randomization before bronchodilator use The measured value is ≤80% of the normal predicted value;\n* Must have experienced at least one severe acute asthma attack within 12 months outbreak event.\n* Positive bronchodilator test\n* Subjects and partners agree to take effective contraceptive measures from signing the Informed Consent Form (ICF) to 6 months after the end of treatment\n\nExclusion Criteria:\n\n* Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or other lung diseases that may impair lung function\n* Subjects with malignant tumor within 5 years\n* Received biologics with the same therapeutic purpose within 6 months prior to screening,\n* Women who are breastfeeding or pregnant, or who plan to become pregnant or breastfeeding during the study period;",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Xiaofeng Cai, bachelor",
          "role": "CONTACT",
          "phone": "02151371305",
          "email": "xiaofeng.cai@mabgeek.com"
        }
      ],
      "overallOfficials": [
        {
          "name": "Nanshan Zhong, Medical PhD",
          "affiliation": "The First Affiliated Hospital of Guangzhou Medical University",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "The First Affiliated Hospital of Guangzhou Medical University",
          "status": "RECRUITING",
          "city": "Guangzhou",
          "state": "Guangdong",
          "zip": "510000",
          "country": "China",
          "contacts": [
            {
              "name": "Jing Li, Medical Ph.D",
              "role": "CONTACT"
            }
          ],
          "geoPoint": {
            "lat": 23.11667,
            "lon": 113.25
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001249",
          "term": "Asthma"
        }
      ],
      "ancestors": [
        {
          "id": "D001982",
          "term": "Bronchial Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D008173",
          "term": "Lung Diseases, Obstructive"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}